Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.349, Iss.2, 1998-05, pp. : 151-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The dopamine D₁ receptor agonist and D₂ receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rats

By Milivojevič Nataša Krisch Igor Sket Dušan Živin Marko

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 369, Iss. 6, 2004-06 ,pp. : 576-582

Springer Publishing Company

Access to resources Recommend Favorite

Bromocriptine/cabergoline/oxcarbazepine interaction: Reduced clinical efficacy leading to prolactinoma progression (first report of an interaction between cabergoline and oxcarbazepine): case report

Reactions Weekly, Vol. 1, Iss. 1416, 2012-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Drug interaction potential of resveratrol

By Detampel Pascal Beck Mareike Krähenbühl Stephan Huwyler Jörg

Drug Metabolism Reviews, Vol. 44, Iss. 3, 2012-08 ,pp. : 253-265

Informa Healthcare

Access to resources Recommend Favorite

Antiparkinsonian Medication and Pathological Gambling

By Lader Malcolm

CNS Drugs, Vol. 22, Iss. 5, 2008-01 ,pp. : 407-416

Adis International

Access to resources Recommend Favorite

Bromocriptine: Hypersexuality: case report

Reactions Weekly, Vol. 1, Iss. 1394, 2012-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite